Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

The FDA has granted fast track designation to HLD-0915 for the treatment of metastatic castration-resistant prostate cancer.

Subspecialization in oncology is increasing in the United States, but it varies across cancer types and regions, data suggest.

Both doctors and patients should pay attention to blood glucose monitoring and manage hyperglycemia,” the researchers wrote.